



# AB International Health Care Portfolio

## Strategy

Seeks growth of capital by:

- Investing primarily in equity securities of health care and health care-related companies located throughout the world
- Employing rigorous bottom-up research to identify companies with long-term growth potential in various market conditions by focusing on those with a history of high returns on invested capital, strong free cash flows and attractive valuations
- Emphasizing companies that are expected to attract health care spending, generally through the introduction of new treatments and therapies or by offering customers cost reduction opportunities

## Profile

The Portfolio will suit higher-risk-tolerant investors seeking the medium- to long-term rewards of equity investment.

- Fund Inception:** 20/07/1983
- Domicile:** Luxembourg
- Fiscal Year End:** 31-May
- Subscription/Redemption:** Daily
- Net Assets:** \$3.237,54 million
- Total # of Holdings:** 45
- Active Share:** 63,00%
- Order Placement Cutoff Time:** 4PM US ET
- Base Currency:** US Dollar
- Reporting Currencies:** Euro
- Benchmark:** MSCI World Health Care Index<sup>1</sup>
- Fund Type:** SICAV

## Portfolio Management & Experience


- John H. Fogarty, CFA:** 29 years
- Vinay Thapar:** 22 years

## Risk & Reward Profile



This synthetic risk and reward indicator (SRRI) scale rating indicates how the Portfolio may perform and the risk of losing some or all of your capital. The SRRI is from the most recent KIID, available from our website, and may be subject to change.

## Growth of USD 10,000



## Complete 12 Month Returns %

Class	01/18 12/18	01/19 12/19	01/20 12/20	01/21 12/21	01/22 12/22
A USD	4,26	20,08	18,44	23,27	-10,37
A EUR	9,16	22,61	8,82	32,26	-4,67
Benchmark	2,51	23,24	13,52	19,80	-5,41

**Past performance does not guarantee future results.** The performance shown above is net of ongoing charges and assumes an investment of USD 10,000 at inception of the share class, on which an investor may pay a sales charge of up to 5%. If this charge were deducted from the initial investment, an investor would need to pay USD 10,527 in order to achieve an investment of USD 10,000. For investors, other personal securities portfolio costs (e.g., custody fees), if applicable may further reduce performance.

## Performance % (Returns Are Annualized For Periods Longer Than One Year)

Class	1 Month	YTD	1 Year	3 Years	5 Years	10 Years	Since Inception
A USD	-3,09	-10,37	-10,37	9,38	10,38	12,26	7,92
A EUR	-5,79	-4,67	-4,67	11,12	12,93	14,63	4,57
Benchmark	-1,18	-5,41	-5,41	8,76	10,20	12,02	9,84 <sup>^</sup>

**Past performance does not guarantee future results.** <sup>^</sup>Since inception performance is from closest month-end after inception date of Class A USD. See page 2 for inception dates.

## Calendar Year Performance %

Class	2018	2019	2020	2021	2022
A USD	4,26	20,08	18,44	23,27	-10,37
A EUR	9,16	22,61	8,82	32,26	-4,67
Benchmark	2,51	23,24	13,52	19,80	-5,41

**Past performance does not guarantee future results.** The value of investments and the income from them will vary. Your capital is at risk. Performance data are provided in the share class currency, and include the change in net asset value and the reinvestment of any distributions paid on Portfolio shares for the period shown. Performance data are net of management fees, but do not reflect sales charges or the effect of taxes. Returns for other share classes will vary due to different charges and expenses.

**Source:** AllianceBernstein (AB).

## NOTES

**'The Portfolio uses the Benchmark shown for comparison purposes only. The Portfolio is actively managed and the Investment Manager is not constrained by its Benchmark when implementing the Portfolio's investment strategy.** The MSCI World Health Care Index is a free float-adjusted market capitalization index that is designed to measure global developed market equity performance for the Health Care Sector. The MSCI World Health Care Index consists of 23 developed market country indices. An investor cannot invest directly in an index, and their results are not indicative of the performance for any specific investment, including an AB fund. Indices do not include sales charges or operating expenses associated with an investment in a mutual fund, which would reduce total returns.

## Share Class Information

Class	ISIN	Bloomberg	Inception	Dist. Yield <sup>2</sup>	Dividend <sup>3</sup>	Net Asset Value <sup>4</sup>
A USD	LU0058720904	ALLHCFA:LX	05/07/1995	-	-	506,89
A EUR	LU0251853072	ALLHCFE:LX	24/11/2000	-	-	473,47

## NOTES

<sup>2</sup>Yields are calculated based on the latest available distribution rate per share for a particular class. The yield is not guaranteed and will fluctuate.

<sup>3</sup>For distributing classes, a Portfolio may pay dividends from gross income (before reduction for fees and expenses), realized and unrealized gains, and capital attributable to the relevant class. Investors should note that distributions in excess of net income (gross income less fees and expenses) may represent a return of the investor's original investment amount and as such may result in a decrease in the net asset value per unit for the relevant class. Distributions out of capital may be taxed as income in certain jurisdictions.

<sup>4</sup>Net asset value is denominated in the share class currency.

## Fees &amp; Charges

Class	Max Entry Charge %*	Exit Charge	Ongoing Charge %	Performance Fee
A USD	5,00	none	1,96	none
A EUR	5,00	none	1,96	none

Ongoing charges include fees and certain expenses of the Portfolio as of the most recent KIID, and may be subject to a cap which is reflected above if applicable. Full details of the charges are available in the Portfolio's prospectus. \*This is the maximum figure; the entry charge may be less than this.

## Holdings &amp; Allocations

Top Ten Holdings	Industry	%
UnitedHealth Group, Inc.	Health Care Providers & Services	8,73
Novo Nordisk A/S	Pharmaceuticals	7,42
Roche Holding AG	Pharmaceuticals	6,35
Elevar Health, Inc.	Health Care Providers & Services	5,26
Amgen, Inc.	Biotechnology	5,13
Vertex Pharmaceuticals	Biotechnology	4,38
Regeneron Pharmaceuticals	Biotechnology	3,82
GSK PLC	Pharmaceuticals	3,70
Gilead Sciences, Inc.	Biotechnology	3,05
Intuitive Surgical, Inc.	Health Care Equipment & Supplies	2,95
<b>Total</b>		<b>50,79</b>

Industry Allocation	%
Pharmaceuticals	29,00
Biotechnology	21,23
Health Care Providers & Services	17,43
Health Care Equipment & Supplies	13,06
Life Sciences Tools & Services	10,09
Health Care Technology	3,35
IT Services	1,76
Personal Products	0,38
Cash & Other	3,70

Country Allocation	%
United States	67,06
Denmark	12,39
Switzerland	9,79
Japan	5,11
Australia	2,06
France	1,89
Germany	0,63
Luxembourg	0,58
India	0,30
Other	0,19

**Source: AllianceBernstein (AB).** Portfolio holdings and weightings are subject to change.

**Investment Risks To Consider** These and other risks are described in the Portfolio's prospectus.

**Investment in the Portfolio entails certain risks.** Investment returns and principal value of the Portfolio will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Some of the principal risks of investing in the Portfolio include:

**Emerging-Markets Risk:** Where the Portfolio invests in emerging markets, these assets are generally smaller and more sensitive to economic and political factors, and may be less easily traded, which could cause a loss to the Portfolio.

**Focused Portfolio Risk:** Investing in a limited number of issuers, industries, sectors or countries may subject the Portfolio to greater volatility than one invested in a larger or more diverse array of securities.

**Allocation Risk:** The risk that the allocation of investments between growth and value companies may have a more significant effect on the Portfolio's Net Asset Value (NAV) when one of these strategies is not performing as well as the other. In addition, the transaction costs of rebalancing the investments may, over time, be significant.

**Portfolio Turnover Risk:** A portfolio may be actively managed and turnover may, in response to market conditions, exceed 100%. A higher rate of portfolio turnover increases brokerage and other expenses. High portfolio turnover may also result in the realization of substantial net short-term capital gains, which may be taxable when distributed.

**Derivatives Risk:** The Portfolio may include financial derivative instruments. These may be used to obtain, increase or reduce exposure to underlying assets and may create gearing; their use may result in greater fluctuations of the net asset value.

**OTC Derivatives Counterparty Risk:** Transactions in over-the-counter (OTC) derivatives markets may have generally less governmental regulation and supervision than transactions entered into on organized exchanges. These will be subject to the risk that its direct counterparty will not perform its obligations and that the Portfolio will sustain losses.

**Equity Securities Risk:** The value of equity investments may fluctuate in response to the activities and results of individual companies or because of market and economic conditions. These investments may decline over short- or long-term periods.

**Dividends are not paid for all share classes and are not guaranteed. The Portfolio is meant as a vehicle for diversification and does not represent a complete investment program. Before making an investment decision, prospective investors should read the prospectus carefully and discuss risk and the Portfolio's fees and charges with their financial adviser to determine if the investment is appropriate for them. This financial promotion is directed solely at persons in jurisdictions where the funds and relevant share class are registered or who may otherwise lawfully receive it. Investors should review the Portfolio's full Prospectus, together with the Portfolio's Key Investor Information Document (KIID) or Key Information Document (KID) and the most recent financial statements. Copies of these documents, including the latest annual report and, if issued thereafter, the latest semi-annual report, may be obtained free of charge from AllianceBernstein (Luxembourg) S.à r.l. by visiting [www.alliancebernstein.com](http://www.alliancebernstein.com) or [www.eifs.lu/alliancebernstein](http://www.eifs.lu/alliancebernstein), or in printed form by contacting the local distributor in the jurisdictions in which the funds are authorised for distribution.**

**Investors are encouraged to consult their independent financial advisors regarding the suitability of Shares of the Portfolio for their investment needs.**

**Past performance does not guarantee future results.** The actual return achieved by investors in other currencies may increase or decrease as a result of currency fluctuations. Currency-hedged share classes use hedging techniques in an attempt to reduce—but not eliminate—fluctuations between the investor's holdings in a particular currency-hedged share class denominated in the investor's investing currency and the Portfolio's base currency. The goal is to deliver returns that track the Portfolio's base currency returns more closely.

**Note to All Readers:** This document has been approved by AllianceBernstein Limited, an affiliate of AllianceBernstein L.P. The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this publication. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized.

**Note to Readers in Europe:** This information is issued by AllianceBernstein (Luxembourg) S.à r.l. Société à responsabilité limitée, R.C.S. Luxembourg B 34 305, 2-4, rue Eugène Ruppert, L-2453 Luxembourg. Authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

Overall Morningstar Rating is a copyright of Morningstar, Inc., 2023. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Shares of AB funds are offered only pursuant to the current prospectus together with the most recent financial statements. The information on this page is for information purposes only and should not be construed as an offer to sell, or solicitation of an offer to buy, or a recommendation for the securities of any AB fund.

